alert: Assessment of LEscol in Renal Transplantation
principal researchers
Bengt Fellström (Uppsala University, Sweden)
Hallvard Holdaas (Oslo University Hospital, Norway)
Terje R Pedersen (University of Oslo, Norway)
data CUSTODIAN
Novartis Pharma AG
funding
Novartis Pharma AG
key publications
- Design paper: J Cardiovasc Risk 2001; 8: 63–71
- Main results: Lancet 2003; 361: 2024–31
- Effect on renal endpoints: Kidney Int 2004; 66(4):1549-55
- Long-term follow-up: Am J Transplant 2005; 5: 2929–2936
- Effect by gender: Clin Transplant 2006; 20(3): 374-82
- Effect on cerebrovascular events: Transplantation 2009; 87(1): 112-7
- Inflammation markers: Clin J Am Soc Nephrol 2009; 4(7): 1246-54
- Effect in those with Systemic Lupus Erythematosus: Arthritis Rheum 2009; 60(4): 1060-4
- Osteoprotegerin as predictor of renal and CV outcomes: Nephrol Dial Transplant 2012; 27(6):2571-5